Endocrine Disruption Screening Market Growth Sturdy at 2.8 % CAGR to Outstrip USD 153.30 Million by 2028 COVID-19 Impact and Global Analysis by The…

Growing Prevalence of Endocrine Disorders Drives Endocrine Disruption Screening Market Growth

The endocrine disruption screening market is projected to reach US$ 153.30 million by 2028 from US$ 126.53 million in 2021; it is expected to grow at a CAGR of 2.8% during 2021 to 2028.

According to our new research study on Endocrine Disruption Screening Market Forecast to 2028 COVID-19 Impact and Global Analysis by Assay Type, Application, Source of Waste, Method, End-User and Geography. The report highlights trends prevailing in the market and factors driving its growth. The growth of the market is attributed to the growing research in the biotechnology sector and the rising prevalence of endocrine disorders. However, the high cost of screening technology hampers the market growth.

Get Sample PDF Copy of Endocrine Disruption Screening Market at: https://www.theinsightpartners.com/sample/TIPRE00025912/

Acromegaly (overproduction of growth hormone), obesity, metabolic syndrome, impaired fasting glucose, impaired glucose tolerance, osteoporosis, osteopenia, mild-moderate hypovitaminosis D, erectile dysfunction, dyslipidemia, and thyroiditis are among the endocrine disorders that have a collective prevalence of at least 5% among the adults in the US. Of these conditions, Males have the highest incidence of erectile dysfunction, while females have the highest incidence of osteopenia/osteoporosis. Diabetes mellitus in children and pituitary adenoma are the least common conditions, affecting less than 1% of the US population. Adrenocortical carcinoma, pheochromocytoma, and pituitary adenomas are the conditions with the lowest incidence. Hyperparathyroidism and thyroid disorders are more common in women. Diabetes mellitus is most prevalent among ethnic minorities. Endocrine and metabolic diseases are among the most common modern human ailments, particularly in the US and other countries implementing ample nutrition and screening programs for high-risk individuals. Endocrine disorders such as hyperparathyroidism, primary and secondary hypogonadism, GH deficiency, and hypothyroidism can lead to other disorders, such as metabolic bone disease and diabetes mellitus. Thus, the growing prevalence and incidence of such conditions propel the demand for endocrine disruption screening products.

North America held the largest share of the global endocrine disruption screening market in 2021. The US held the largest share of the North American market in 2021. The US market is expected to grow in the coming years due to the increasing adoption of technological advancements and the rising emphasis on the assessment of endocrine disruptor chemicals in agriculture pesticide use, sewage treatment plants, cosmetics and many other fields.

Impact of COVID-19 Pandemic on Endocrine Disruption Screening Market

The COVID-19 pandemic is adversely affecting industries worldwide. The outbreak led to significant disruptions in primary industries, such as manufacturing, healthcare, energy & power, electronics & semiconductor, aerospace & defense, and construction in 2020. The pandemic had a negative impact on the total sales of most companies, whereas it had a favorable impact on the endocrine disruption screening market due to the increased usage of endocrine disruption screening technologies for various hormonal disorders. The lockdown due to the COVID-19 pandemic has forced people to put off getting their hormonal health checked, thus affecting the number of tests being performed and sales of screening products. Due to the COVID-19 pandemic, dealing with hormonal and mental health has become a major medical concern across the world.

Have Question? Speak to Analyst at: https://www.theinsightpartners.com/speak-to-analyst/TIPRE00025912

Creative Bioarray; Charles River Laboratories, Inc; Eurofins Scientific; Alpha Analytical, Inc.; JRF Global; Xenometrix AG; SGS SA; Smithers; and Mrieux NutriSciences are among the leading companies in the endocrine disruption screening market.

The endocrine disruption screening market, by assay type, is bifurcated into in-vitro and in-vivo. Based on application, the market is bifurcated into natural materials and synthetic materials. Based on source of waste, the endocrine disruption screening market is segmented into incineration and landfill, agricultural runoff, industrial and municipal effluents, pulp mill effluents, consumer products, and others. Based on method, the market is segmented into estrogen receptor (ER) transactivation, androgen receptor (AR) transactivation, androgen receptor (AR) modulation, estrogen receptor-alpha (ER) binding, estrogen receptor beta (ER) binding, androgen receptor (AR) binding, steroidogenesis, aromatase assay, and others. Based on end user, the endocrine disruption screening market is segmented into pharmaceutical and biopharmaceutical companies, cosmetics and household product companies, food industry, and chemical industry. By geography, the endocrine disruption screening market is segmented into North America (the US, Canada, and Mexico), Europe (the UK, Germany, France, Italy, Spain, and the Rest of Europe), Asia Pacific (China, Japan, India, Australia, South Korea, and the Rest of Asia Pacific), the Middle East and Africa (the UAE, Saudi Arabia, South Africa, and the Rest of the Middle East and Africa), and South and Central America (Brazil, Argentina, and the Rest of South and Central America).

Global metabolomics market players and research institutes are constantly involved in activities to study the various aspects of metabolomics to extend its range of applications. The pharmaceuticals, biotechnological, and other companies outsource several processes to reduce cost and produce results in less time. The research and development (R&D) process plays a crucial role in the growth of these businesses. For pharmaceuticals and biotech companies, R&D is necessary for the development of new molecules with greater medical and commercial potential for various therapeutic applications. The companies invest majorly in R&Ds with the aim of delivering high-quality and innovative products to the market. Metabolomics is widely used by these players as part of their development processes, and they opt for outsourcing the metabolomics studies to CROs offering these services. Following are the recent R&D investments made by a few international pharmaceutical and biotechnology companies.

Order a Copy of Endocrine Disruption Screening Market Shares, Strategies and Forecasts to 2028 Research Report at:https://www.theinsightpartners.com/buy/TIPRE00025912/

About Us:

The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We specialize in industries such as Semiconductor and Electronics, Aerospace and Defense, Automotive and Transportation, Biotechnology, Healthcare IT, Manufacturing and Construction, Medical Device, Technology, Media and Telecommunications, Chemicals and Materials.

If you have any queries about this report or if you would like further information, please contact us:

Contact Person:Sameer Joshi

E-mail: [emailprotected]

Phone:+1-646-491-9876

Press Release: https://www.theinsightpartners.com/pr/endocrine-disruption-screening-market

See the original post:

Endocrine Disruption Screening Market Growth Sturdy at 2.8 % CAGR to Outstrip USD 153.30 Million by 2028 COVID-19 Impact and Global Analysis by The...